M&A Deal Summary

Singleron Acquires Proteona

On March 7, 2022, Singleron acquired life science company Proteona

Acquisition Highlights
  • This is Singleron’s 1st transaction in the Life Science sector.
  • This is Singleron’s 1st transaction in Singapore.

M&A Deal Summary

Date 2022-03-07
Target Proteona
Sector Life Science
Buyer(s) Singleron
Deal Type Add-on Acquisition

Target

Proteona

Singapore, Singapore
Proteona is a Singapore-based precision medicine company offering single-cell biomarker discovery services to translational and clinical researchers across the globe. Proteona provides a comprehensive sample-to-answer service that enables users to phenotype cells using standard protein markers and gains a deeper understanding of cell activity based upon their gene expression profiles. Proteona was founded in 2017 and is based in Singapore.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Singleron

Jiangsu, China

Category Company
Founded 2018
Sector Life Science
DESCRIPTION

Singleron develops and commercializes single-cell multi-omics products that can be used in both research and clinical settings. Singleron's current product portfolio includes instruments, microfluidic devices, reagents, software analysis, and database solutions that facilitate high-throughput single-cell analysis. The company currently has offices, laboratories, and manufacturing facilities in China, Germany, and the US. Its products are used in over 1,000 laboratories including hospitals, research institutes, and pharmaceutical companies. Singleron was founded in 2018 and is based in Jiangsu, China.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Singapore M&A 1 of 1
Year: 2022 M&A 1 of 1